Aditxt, Inc. Files Amendment to Form 8-K
Ticker: ADTX · Form: 8-K/A · Filed: Aug 18, 2025 · CIK: 1726711
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
Aditxt filed an amendment to its 8-K, updating financial docs from Dec 2023.
AI Summary
Aditxt, Inc. filed an amendment (No. 6) to its Form 8-K on August 18, 2025, related to financial statements and exhibits as of December 11, 2023. The company, formerly known as Aditx Therapeutics, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing is an amendment to a previous report, indicating updates or corrections to financial statements and exhibits, which could be important for investors assessing the company's financial position.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, not indicating new material events or significant financial changes.
Key Players & Entities
- Aditxt, Inc. (company) — Registrant
- Aditx Therapeutics, Inc. (company) — Former company name
- December 11, 2023 (date) — Date of earliest event reported
- August 18, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the purpose of this Form 8-K/A filing?
This filing is Amendment No. 6 to Form 8-K, reporting on financial statements and exhibits as of December 11, 2023.
When was the earliest event reported in this filing?
The earliest event reported is dated December 11, 2023.
What is Aditxt, Inc.'s former company name?
Aditxt, Inc. was formerly known as Aditx Therapeutics, Inc.
In which state is Aditxt, Inc. incorporated?
Aditxt, Inc. is incorporated in Delaware.
What is the SIC code for Aditxt, Inc.?
The Standard Industrial Classification (SIC) code for Aditxt, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,414 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2025-08-18 06:51:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 ADTX The Nasdaq Stock Market LLC
- $1.5 million — eptember 30, 2025 and add an additional $1.5 million parent investment from Aditxt to Evofem
Filing Documents
- ea0253649-8ka_aditxt.htm (8-K/A) — 36KB
- ea025364901ex99-1_aditxt.htm (EX-99.1) — 723KB
- ea025364901ex99-2_aditxt.htm (EX-99.2) — 147KB
- 0001213900-25-077698.txt ( ) — 1202KB
- adtx-20231211.xsd (EX-101.SCH) — 3KB
- adtx-20231211_lab.xml (EX-101.LAB) — 33KB
- adtx-20231211_pre.xml (EX-101.PRE) — 22KB
- ea0253649-8ka_aditxt_htm.xml (XML) — 5KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (a) Financial statements of business or funds acquired. The unaudited condensed consolidated balance sheets of Evofem and subsidiaries as of June 30, 2025 and December 31, 2024, and the related unaudited condensed consolidated statements of operations, comprehensive operations, convertible and redeemable preferred stock and stockholders' deficit, and cash flows for each of the three and six months ended June 30, 2025 and 2024, respectively, are filed as Exhibit 99.1 hereto and are incorporated herein by reference. (b) Pro forma financial information. The unaudited pro forma condensed consolidated combined financial information of the Company giving pro forma effect to the acquisition of Evofem, consisting of (i) unaudited pro forma consolidated statement of financial position as of June 30, 2025, and (ii) unaudited consolidated pro forma statement of earnings for the six months ended June 30, 2025, are filed as Exhibit 99.2. (d) Exhibits. Exhibit No. Exhibit 99.1 Unaudited financial statements of Evofem Biosciences, Inc. and Subsidiaries as of and for the six months ended June 30, 2025 and 2024 99.2 Unaudited pro forma consolidated financial statements as of and for the six months ended June 30, 2025 104 Cover Page Interactive Data File (embedded within the XBRL document) -2-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADITXT, INC. Date: August 18, 2025 By: /s/ Amro Albanna Amro Albanna Chief Executive Officer -3-